Global Viral Vector-Based Cell & Gene Therapy CDMO Market Growth (Status and Outlook) 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Viral Vector-Based Cell & Gene Therapy CDMO market size is predicted to grow from US$ 154 million in 2025 to US$ 326 million in 2031; it is expected to grow at a CAGR of 13.4% from 2025 to 2031.
Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.
United States market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Viral Vector-Based Cell & Gene Therapy CDMO players cover AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Viral Vector-Based Cell & Gene Therapy CDMO Industry Forecast” looks at past sales and reviews total world Viral Vector-Based Cell & Gene Therapy CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector-Based Cell & Gene Therapy CDMO sales for 2025 through 2031. With Viral Vector-Based Cell & Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector-Based Cell & Gene Therapy CDMO industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector-Based Cell & Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector-Based Cell & Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector-Based Cell & Gene Therapy CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector-Based Cell & Gene Therapy CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector-Based Cell & Gene Therapy CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector-Based Cell & Gene Therapy CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global Viral Vector-Based Cell & Gene Therapy CDMO market size is predicted to grow from US$ 154 million in 2025 to US$ 326 million in 2031; it is expected to grow at a CAGR of 13.4% from 2025 to 2031.
Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.
United States market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Viral Vector-Based Cell & Gene Therapy CDMO players cover AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Viral Vector-Based Cell & Gene Therapy CDMO Industry Forecast” looks at past sales and reviews total world Viral Vector-Based Cell & Gene Therapy CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector-Based Cell & Gene Therapy CDMO sales for 2025 through 2031. With Viral Vector-Based Cell & Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector-Based Cell & Gene Therapy CDMO industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector-Based Cell & Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector-Based Cell & Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector-Based Cell & Gene Therapy CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector-Based Cell & Gene Therapy CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector-Based Cell & Gene Therapy CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector-Based Cell & Gene Therapy CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Adeno-associated Viral
- Adenoviral
- Lentiviral
- Retroviral
- Gene Therapy
- Cell Therapy
- Vaccine Development
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AGC Biologics
- Lonza
- Charles River Laboratories
- Thermo Fisher Scientific
- SK pharmteco
- Exothera
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)
2.1.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Viral Vector-Based Cell & Gene Therapy CDMO by Country/Region (2020, 2024 & 2031)
2.2 Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type
2.2.1 Adeno-associated Viral
2.2.2 Adenoviral
2.2.3 Lentiviral
2.2.4 Retroviral
2.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
2.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
2.4 Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application
2.4.1 Gene Therapy
2.4.2 Cell Therapy
2.4.3 Vaccine Development
2.5 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
2.5.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
3 VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO MARKET SIZE BY PLAYER
3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Player
3.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Player (2020-2025)
3.1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO BY REGION
4.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025)
4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.4 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.5 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)
5.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
5.3 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025)
6.2 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
6.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)
7.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
7.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO by Region (2020-2025)
8.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO MARKET FORECAST
10.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.5 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.2 Canada Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.3 Mexico Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.4 Brazil Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.3.1 China Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast
10.3.2 Japan Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.3 Korea Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.4 Southeast Asia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.5 India Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.6 Australia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.2 France Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.3 UK Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.4 Italy Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.5 Russia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.2 South Africa Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.3 Israel Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.4 Turkey Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Type (2026-2031)
10.7 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 AGC Biologics
11.1.1 AGC Biologics Company Information
11.1.2 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AGC Biologics Main Business Overview
11.1.5 AGC Biologics Latest Developments
11.2 Lonza
11.2.1 Lonza Company Information
11.2.2 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Lonza Main Business Overview
11.2.5 Lonza Latest Developments
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Information
11.3.2 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Charles River Laboratories Main Business Overview
11.3.5 Charles River Laboratories Latest Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Information
11.4.2 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Thermo Fisher Scientific Main Business Overview
11.4.5 Thermo Fisher Scientific Latest Developments
11.5 SK pharmteco
11.5.1 SK pharmteco Company Information
11.5.2 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 SK pharmteco Main Business Overview
11.5.5 SK pharmteco Latest Developments
11.6 Exothera
11.6.1 Exothera Company Information
11.6.2 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Exothera Main Business Overview
11.6.5 Exothera Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)
2.1.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Viral Vector-Based Cell & Gene Therapy CDMO by Country/Region (2020, 2024 & 2031)
2.2 Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type
2.2.1 Adeno-associated Viral
2.2.2 Adenoviral
2.2.3 Lentiviral
2.2.4 Retroviral
2.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
2.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
2.4 Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application
2.4.1 Gene Therapy
2.4.2 Cell Therapy
2.4.3 Vaccine Development
2.5 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
2.5.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
3 VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO MARKET SIZE BY PLAYER
3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Player
3.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Player (2020-2025)
3.1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO BY REGION
4.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025)
4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.4 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.5 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)
5.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
5.3 Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025)
6.2 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
6.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)
7.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
7.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO by Region (2020-2025)
8.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL VIRAL VECTOR-BASED CELL & GENE THERAPY CDMO MARKET FORECAST
10.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.1.5 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2 Americas Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.2 Canada Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.3 Mexico Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.2.4 Brazil Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3 APAC Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.3.1 China Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast
10.3.2 Japan Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.3 Korea Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.4 Southeast Asia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.5 India Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.3.6 Australia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.2 France Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.3 UK Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.4 Italy Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.4.5 Russia Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.2 South Africa Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.3 Israel Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.5.4 Turkey Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
10.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Type (2026-2031)
10.7 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Viral Vector-Based Cell & Gene Therapy CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 AGC Biologics
11.1.1 AGC Biologics Company Information
11.1.2 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AGC Biologics Main Business Overview
11.1.5 AGC Biologics Latest Developments
11.2 Lonza
11.2.1 Lonza Company Information
11.2.2 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Lonza Main Business Overview
11.2.5 Lonza Latest Developments
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Information
11.3.2 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Charles River Laboratories Main Business Overview
11.3.5 Charles River Laboratories Latest Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Information
11.4.2 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Thermo Fisher Scientific Main Business Overview
11.4.5 Thermo Fisher Scientific Latest Developments
11.5 SK pharmteco
11.5.1 SK pharmteco Company Information
11.5.2 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 SK pharmteco Main Business Overview
11.5.5 SK pharmteco Latest Developments
11.6 Exothera
11.6.1 Exothera Company Information
11.6.2 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
11.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Exothera Main Business Overview
11.6.5 Exothera Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Viral Vector-Based Cell & Gene Therapy CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Adeno-associated Viral
Table 4. Major Players of Adenoviral
Table 5. Major Players of Lentiviral
Table 6. Major Players of Retroviral
Table 7. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Table 10. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Table 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player (2020-2025)
Table 15. Viral Vector-Based Cell & Gene Therapy CDMO Key Players Head office and Products Offered
Table 16. Viral Vector-Based Cell & Gene Therapy CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country (2020-2025)
Table 25. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Table 27. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Table 29. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Table 31. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country (2020-2025)
Table 35. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Viral Vector-Based Cell & Gene Therapy CDMO
Table 41. Key Market Challenges & Risks of Viral Vector-Based Cell & Gene Therapy CDMO
Table 42. Key Industry Trends of Viral Vector-Based Cell & Gene Therapy CDMO
Table 43. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AGC Biologics Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 48. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 49. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AGC Biologics Main Business
Table 51. AGC Biologics Latest Developments
Table 52. Lonza Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 53. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 54. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Lonza Main Business
Table 56. Lonza Latest Developments
Table 57. Charles River Laboratories Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 58. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 59. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Charles River Laboratories Main Business
Table 61. Charles River Laboratories Latest Developments
Table 62. Thermo Fisher Scientific Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 63. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 64. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. Thermo Fisher Scientific Main Business
Table 66. Thermo Fisher Scientific Latest Developments
Table 67. SK pharmteco Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 68. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 69. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. SK pharmteco Main Business
Table 71. SK pharmteco Latest Developments
Table 72. Exothera Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 73. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 74. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Exothera Main Business
Table 76. Exothera Latest Developments
Table 1. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Viral Vector-Based Cell & Gene Therapy CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Adeno-associated Viral
Table 4. Major Players of Adenoviral
Table 5. Major Players of Lentiviral
Table 6. Major Players of Retroviral
Table 7. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Table 10. Viral Vector-Based Cell & Gene Therapy CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Table 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player (2020-2025)
Table 15. Viral Vector-Based Cell & Gene Therapy CDMO Key Players Head office and Products Offered
Table 16. Viral Vector-Based Cell & Gene Therapy CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country (2020-2025)
Table 25. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Table 27. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Table 29. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Table 31. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country (2020-2025)
Table 35. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Viral Vector-Based Cell & Gene Therapy CDMO
Table 41. Key Market Challenges & Risks of Viral Vector-Based Cell & Gene Therapy CDMO
Table 42. Key Industry Trends of Viral Vector-Based Cell & Gene Therapy CDMO
Table 43. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AGC Biologics Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 48. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 49. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AGC Biologics Main Business
Table 51. AGC Biologics Latest Developments
Table 52. Lonza Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 53. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 54. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Lonza Main Business
Table 56. Lonza Latest Developments
Table 57. Charles River Laboratories Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 58. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 59. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Charles River Laboratories Main Business
Table 61. Charles River Laboratories Latest Developments
Table 62. Thermo Fisher Scientific Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 63. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 64. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. Thermo Fisher Scientific Main Business
Table 66. Thermo Fisher Scientific Latest Developments
Table 67. SK pharmteco Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 68. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 69. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. SK pharmteco Main Business
Table 71. SK pharmteco Latest Developments
Table 72. Exothera Details, Company Type, Viral Vector-Based Cell & Gene Therapy CDMO Area Served and Its Competitors
Table 73. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Offered
Table 74. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Exothera Main Business
Table 76. Exothera Latest Developments
LIST OF FIGURES
Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Viral Vector-Based Cell & Gene Therapy CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Viral Vector-Based Cell & Gene Therapy CDMO Sales Market Share by Country/Region (2024)
Figure 8. Viral Vector-Based Cell & Gene Therapy CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type in 2024
Figure 10. Viral Vector-Based Cell & Gene Therapy CDMO in Gene Therapy
Figure 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Gene Therapy (2020-2025) & ($ millions)
Figure 12. Viral Vector-Based Cell & Gene Therapy CDMO in Cell Therapy
Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Cell Therapy (2020-2025) & ($ millions)
Figure 14. Viral Vector-Based Cell & Gene Therapy CDMO in Vaccine Development
Figure 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Vaccine Development (2020-2025) & ($ millions)
Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application in 2024
Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player in 2024
Figure 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Figure 19. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 20. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 21. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 23. Americas Viral Vector-Based Cell & Gene Therapy CDMO Value Market Share by Country in 2024
Figure 24. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region in 2024
Figure 29. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 30. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 31. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 35. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country in 2024
Figure 38. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 39. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 40. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 41. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 54. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 55. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 57. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 58. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 59. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 60. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 61. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 62. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 63. Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 65. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 66. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 67. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 68. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 69. UK Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 70. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 71. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 72. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 73. South Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 74. Israel Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 75. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 76. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Viral Vector-Based Cell & Gene Therapy CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Viral Vector-Based Cell & Gene Therapy CDMO Sales Market Share by Country/Region (2024)
Figure 8. Viral Vector-Based Cell & Gene Therapy CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type in 2024
Figure 10. Viral Vector-Based Cell & Gene Therapy CDMO in Gene Therapy
Figure 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Gene Therapy (2020-2025) & ($ millions)
Figure 12. Viral Vector-Based Cell & Gene Therapy CDMO in Cell Therapy
Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Cell Therapy (2020-2025) & ($ millions)
Figure 14. Viral Vector-Based Cell & Gene Therapy CDMO in Vaccine Development
Figure 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market: Vaccine Development (2020-2025) & ($ millions)
Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application in 2024
Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Player in 2024
Figure 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Figure 19. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 20. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 21. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2020-2025 ($ millions)
Figure 23. Americas Viral Vector-Based Cell & Gene Therapy CDMO Value Market Share by Country in 2024
Figure 24. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region in 2024
Figure 29. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 30. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 31. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 35. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Country in 2024
Figure 38. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 39. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 40. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 41. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 54. APAC Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 55. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 57. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 58. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 59. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 60. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 61. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 62. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 63. Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 65. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 66. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 67. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 68. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 69. UK Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 70. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 71. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 72. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 73. South Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 74. Israel Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 75. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
Figure 76. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size 2026-2031 ($ millions)
